BR112018013387A2 - vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit - Google Patents
vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kitInfo
- Publication number
- BR112018013387A2 BR112018013387A2 BR112018013387-6A BR112018013387A BR112018013387A2 BR 112018013387 A2 BR112018013387 A2 BR 112018013387A2 BR 112018013387 A BR112018013387 A BR 112018013387A BR 112018013387 A2 BR112018013387 A2 BR 112018013387A2
- Authority
- BR
- Brazil
- Prior art keywords
- vaccine
- kit
- pharmaceutical composition
- vaccination vector
- recombinant
- Prior art date
Links
- 238000002255 vaccination Methods 0.000 title abstract 7
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 241000700605 Viruses Species 0.000 title 1
- 241000700721 Hepatitis B virus Species 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/29—Hepatitis virus
- A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
a presente invenção diz respeito a um vetor de vacinação recombinante melhorado para o tratamento ou vacinação contra o vírus da hepatite b (hbv) bem como composições farmacêuticas ou vacinas compreendendo o referido vetor de vacinação recombinante. a presente invenção também diz respeito a um vetor de vacinação recombinante para uso em um método de vacinação contra o hbv, bem como kits compreendendo uma vacina que compreende o vetor de vacinação recombinante.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
LU92942 | 2016-01-12 | ||
LU92942 | 2016-01-12 | ||
PCT/EP2017/050553 WO2017121791A1 (en) | 2016-01-12 | 2017-01-12 | Means and methods for treating hbv |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112018013387A2 true BR112018013387A2 (pt) | 2019-03-06 |
Family
ID=55237880
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018013387-6A BR112018013387A2 (pt) | 2016-01-12 | 2017-01-12 | vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit |
Country Status (21)
Country | Link |
---|---|
US (1) | US10912827B2 (pt) |
EP (1) | EP3402888B1 (pt) |
JP (1) | JP6743154B2 (pt) |
KR (1) | KR20180100228A (pt) |
CN (2) | CN116732101A (pt) |
AU (1) | AU2017207764B2 (pt) |
BR (1) | BR112018013387A2 (pt) |
CA (1) | CA3002508A1 (pt) |
DK (1) | DK3402888T3 (pt) |
ES (1) | ES2834698T3 (pt) |
HR (1) | HRP20201873T1 (pt) |
HU (1) | HUE052104T2 (pt) |
IL (1) | IL260525B (pt) |
PL (1) | PL3402888T3 (pt) |
PT (1) | PT3402888T (pt) |
RS (1) | RS61118B1 (pt) |
RU (1) | RU2740802C2 (pt) |
SG (1) | SG11201805229YA (pt) |
SI (1) | SI3402888T1 (pt) |
WO (1) | WO2017121791A1 (pt) |
ZA (1) | ZA201802644B (pt) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20200092A1 (ar) | 2014-11-10 | 2017-06-16 | Alnylam Pharmaceuticals Inc | تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها |
US11052148B2 (en) | 2016-05-30 | 2021-07-06 | Geo Vax, Inc. | Compositions and methods for generating an immune response to hepatitis B virus |
TWI801377B (zh) | 2017-04-18 | 2023-05-11 | 美商阿尼拉製藥公司 | 治療具有b型肝炎病毒(hbv)感染之個體之方法 |
JP2020516673A (ja) * | 2017-04-18 | 2020-06-11 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | B型肝炎ウイルス(hbv)感染を有する対象を処置する方法 |
US11324820B2 (en) | 2017-04-18 | 2022-05-10 | Alnylam Pharmaceuticals, Inc. | Methods for the treatment of subjects having a hepatitis b virus (HBV) infection |
US20210147807A1 (en) * | 2017-06-14 | 2021-05-20 | Helmholtz Zentrum Munchen - Deutsches Forschungszentrum Fur Gesundheit Und Umwelt (Gmbh) | Methods for purifying endoderm and pancreatic endoderm cells derived from human embryonic stem cells |
GB201721069D0 (en) | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B Immunisation regimen and compositions |
GB201721068D0 (en) * | 2017-12-15 | 2018-01-31 | Glaxosmithkline Biologicals Sa | Hepatitis B immunisation regimen and compositions |
MA51312A (fr) * | 2017-12-19 | 2020-10-28 | Bavarian Nordic As | Méthodes et compositions permettant d'induire une réponse immunitaire contre le virus de l'hépatite b (vhb) |
AR114551A1 (es) | 2018-08-13 | 2020-09-16 | Alnylam Pharmaceuticals Inc | COMPOSICIONES DE AGENTES DE ARNhd CONTRA EL VIRUS DE HEPATITIS B (HBV) Y MÉTODOS PARA SU USO |
CN113939527A (zh) * | 2019-01-11 | 2022-01-14 | 新加坡科技研究局 | Hla-a*11:01限制性乙型肝炎病毒(hbv)肽用于鉴别hbv特异性cd8+ t细胞的用途 |
TW202102256A (zh) * | 2019-03-05 | 2021-01-16 | 比利時商葛蘭素史密斯克藍生物品公司 | B型肝炎免疫法及組合物 |
WO2020210628A1 (en) * | 2019-04-10 | 2020-10-15 | Emv Enhance (Hk) Limited | Compositions and methods for improving vaccination of hyporesponsive individuals |
CN114729010A (zh) * | 2019-08-29 | 2022-07-08 | 维尔生物科技有限公司 | 乙型肝炎病毒疫苗 |
CN112972670B (zh) * | 2019-12-13 | 2023-12-19 | 远大赛威信生命科学(南京)有限公司 | 免疫刺激组合物及其用途 |
JP2023513611A (ja) * | 2020-02-14 | 2023-03-31 | ゲオバックス インコーポレイテッド | Sars-cov2に対する免疫応答を誘導するためのワクチン及びその利用 |
CA3188801A1 (en) * | 2020-07-08 | 2022-01-13 | Janssen Sciences Ireland Unlimited Company | Rna replicon vaccines against hbv |
WO2023085956A1 (en) * | 2021-11-09 | 2023-05-19 | Avalia Immunotherapies Limited | Novel therapeutic vaccines |
WO2023145755A1 (ja) * | 2022-01-25 | 2023-08-03 | 公益財団法人川崎市産業振興財団 | 経皮投与用のrnaを含む組成物および当該組成物の投与方法 |
WO2023250522A2 (en) * | 2022-06-25 | 2023-12-28 | Administrators Of The Tulane Educational Fund | Vaccine adjuvants and methods |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6235288B1 (en) * | 1992-08-26 | 2001-05-22 | The Scripps Research Institute | Peptides for inducing cytotoxic T lymphocyte responses to hepatitis B virus |
WO2006125983A1 (en) * | 2005-05-23 | 2006-11-30 | Oxxon Therapeutics Ltd | Compositions for inducing an immune response against hepatitis b |
WO2009056535A2 (en) * | 2007-10-29 | 2009-05-07 | Genimmune N.V. | Methods and kits for inducing a ctl response using a prime boost regimen |
MX2012001592A (es) * | 2009-08-07 | 2012-05-22 | Transgene Sa | Composicion para el tratamiento de la infección del virus de la hepatitis b. |
EP3266464A3 (en) * | 2011-02-12 | 2018-03-14 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis b infection |
KR101281098B1 (ko) * | 2011-06-30 | 2013-07-02 | 주식회사 녹십자 | B형 간염 바이러스 표면 항원상의 에피토프 및 이의 용도 |
CA2948181A1 (en) * | 2014-05-16 | 2015-11-19 | Yale University | Virus like vesicles (vlvs) based vaccines to prevent or treat chronic hepatitis b virus (hbv) infection |
-
2017
- 2017-01-12 JP JP2018535373A patent/JP6743154B2/ja active Active
- 2017-01-12 PT PT177010675T patent/PT3402888T/pt unknown
- 2017-01-12 RS RS20201424A patent/RS61118B1/sr unknown
- 2017-01-12 HU HUE17701067A patent/HUE052104T2/hu unknown
- 2017-01-12 SG SG11201805229YA patent/SG11201805229YA/en unknown
- 2017-01-12 DK DK17701067.5T patent/DK3402888T3/da active
- 2017-01-12 EP EP17701067.5A patent/EP3402888B1/en active Active
- 2017-01-12 US US16/069,268 patent/US10912827B2/en active Active
- 2017-01-12 PL PL17701067T patent/PL3402888T3/pl unknown
- 2017-01-12 CN CN202310549953.2A patent/CN116732101A/zh active Pending
- 2017-01-12 CN CN201780006621.2A patent/CN109154004B/zh active Active
- 2017-01-12 ES ES17701067T patent/ES2834698T3/es active Active
- 2017-01-12 RU RU2018114308A patent/RU2740802C2/ru active
- 2017-01-12 SI SI201730523T patent/SI3402888T1/sl unknown
- 2017-01-12 KR KR1020187023239A patent/KR20180100228A/ko unknown
- 2017-01-12 BR BR112018013387-6A patent/BR112018013387A2/pt unknown
- 2017-01-12 WO PCT/EP2017/050553 patent/WO2017121791A1/en active Application Filing
- 2017-01-12 CA CA3002508A patent/CA3002508A1/en active Pending
- 2017-01-12 AU AU2017207764A patent/AU2017207764B2/en active Active
-
2018
- 2018-04-20 ZA ZA2018/02644A patent/ZA201802644B/en unknown
- 2018-07-10 IL IL260525A patent/IL260525B/en unknown
-
2020
- 2020-11-25 HR HRP20201873TT patent/HRP20201873T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
IL260525B (en) | 2022-02-01 |
RU2740802C2 (ru) | 2021-01-21 |
AU2017207764A1 (en) | 2018-05-10 |
US10912827B2 (en) | 2021-02-09 |
ZA201802644B (en) | 2023-07-26 |
JP6743154B2 (ja) | 2020-08-19 |
CN109154004B (zh) | 2023-06-06 |
SI3402888T1 (sl) | 2021-02-26 |
KR20180100228A (ko) | 2018-09-07 |
ES2834698T3 (es) | 2021-06-18 |
PL3402888T3 (pl) | 2021-04-19 |
RU2018114308A (ru) | 2020-02-13 |
CA3002508A1 (en) | 2017-07-20 |
HRP20201873T1 (hr) | 2021-01-22 |
JP2019505205A (ja) | 2019-02-28 |
CN116732101A (zh) | 2023-09-12 |
SG11201805229YA (en) | 2018-07-30 |
HUE052104T2 (hu) | 2021-04-28 |
EP3402888B1 (en) | 2020-08-26 |
PT3402888T (pt) | 2020-12-04 |
CN109154004A (zh) | 2019-01-04 |
WO2017121791A1 (en) | 2017-07-20 |
EP3402888A1 (en) | 2018-11-21 |
RS61118B1 (sr) | 2020-12-31 |
DK3402888T3 (da) | 2020-11-30 |
US20190030158A1 (en) | 2019-01-31 |
AU2017207764B2 (en) | 2023-04-27 |
RU2018114308A3 (pt) | 2020-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018013387A2 (pt) | vetor de vacinação recombinante, vírus mva, vacina ou composição farmacêutica e kit | |
EP4233898A3 (en) | Influenza mrna vaccines | |
BR112018008090A2 (pt) | vacina de vírus do herpes simplex. | |
BR112018009009A2 (pt) | terapia combinada de um inibidor de formação de capsídeo hbv e um interferon | |
MX2018014573A (es) | Vacuna contra el virus del zika. | |
BR112018008102A2 (pt) | vacina de vírus sincicial respiratório | |
PH12017501370A1 (en) | Bivalent swine influenza virus vaccine | |
BR112018009032A8 (pt) | vetor viral de arenavírus infeccioso, composição farmacêutica, composição imunogênica, vacina, método para o tratamento ou a prevenção de infecção pelo vírus da hepatite b em um paciente, uso de um vetor viral, ácido nucleico isolado, vetor viral de arenavírus infeccioso deficiente em replicação e método para sua geração | |
MX2018004916A (es) | Vacuna contra el virus de la influenza de amplio espectro. | |
BR112018071048A2 (pt) | combinações e métodos que compreendem um inibidor da montagem de capsídeos | |
BR112019004560A2 (pt) | tratamento combinado com agonista de tlr7 e um inibidor de formação de capsídeo de hbv | |
BR112017003462A2 (pt) | coronavírus bovino atenuado, vacina, e, método de vacinação de um bovino. | |
BR112017004197A2 (pt) | composições de vacina contra doenças do vírus da dengue | |
BR112016026721A2 (pt) | vacinas com base em vesículas do tipo vírus (vlvs) para prevenir ou tratar infecção por vírus da hepatite b (hbv) crônica | |
WO2017214596A8 (en) | Compositions and methods for preventing and treating zika virus infection | |
EA201990010A1 (ru) | Вакцина против вируса инфекционного бронхита | |
BR112015021523A2 (pt) | composição de uma vacina contra a tosse convulsa acelular, e, métodos para vacinar um sujeito contra a bordetella pertussis e para proteger um sujeito da tosse convulsa | |
BR112019003992A2 (pt) | vacina contra neisseria meningitidis | |
BR112016024096A2 (pt) | novo bacteriófago e composição compreendendo o mesmo | |
CL2018001946A1 (es) | Virus atenuados de bronquitis infecciosa. | |
MX2018006416A (es) | Metodos para el tratamiento, prevencion y diagnostico de infeccion por el virus de la diarrea epidemica porcina. | |
BR112017002440A2 (pt) | vírus da diarreia epizoótica porcina mutante para utilização em uma vacina | |
BR112018015893A2 (pt) | vacinas de câncer e métodos de tratamento usando as mesmas | |
BR112018074910A2 (pt) | composição imunológica, e, método de indução de uma resposta imunológica contra o vírus da influenza equina em um sujeito | |
MX2017012389A (es) | Vacuna del virus de la parotiditis recombinante jeryl lynn2. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] |